TY - JOUR AU - Center, M. M. AU - Jemal, A. AU - Lortet-Tieulent, J. PY - 2012 DA - 2012// TI - International variation in prostate cancer incidence and mortality rates JO - Eur Urol VL - 61 UR - https://doi.org/10.1016/j.eururo.2012.02.054 DO - 10.1016/j.eururo.2012.02.054 ID - Center2012 ER - TY - JOUR AU - Zhu, Y. AU - Ye, D. PY - 2020 DA - 2020// TI - Chinese Expert Consensus on the Diagnosis and Treatment of Castration-Resistant Prostate Cancer (2019 Update) JO - Cancer Manag Res VL - 12 UR - https://doi.org/10.2147/CMAR.S236879 DO - 10.2147/CMAR.S236879 ID - Zhu2020 ER - TY - JOUR AU - Kwon, E. D. AU - Drake, C. G. AU - Scher, H. I. PY - 2014 DA - 2014// TI - Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(14)70189-5 DO - 10.1016/S1470-2045(14)70189-5 ID - Kwon2014 ER - TY - JOUR AU - Beer, T. M. AU - Kwon, E. D. AU - Drake, C. G. PY - 2017 DA - 2017// TI - Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.69.1584 DO - 10.1200/JCO.2016.69.1584 ID - Beer2017 ER - TY - JOUR AU - Riaz, N. AU - Morris, L. AU - Havel, J. J. AU - Makarov, V. AU - Desrichard, A. AU - Chan, T. A. PY - 2016 DA - 2016// TI - The role of neoantigens in response to immune checkpoint blockade JO - Int Immunol VL - 28 UR - https://doi.org/10.1093/intimm/dxw019 DO - 10.1093/intimm/dxw019 ID - Riaz2016 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Chalmers, Z. R. AU - Connelly, C. F. AU - Fabrizio, D. PY - 2017 DA - 2017// TI - Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden JO - Genome Med VL - 9 UR - https://doi.org/10.1186/s13073-017-0424-2 DO - 10.1186/s13073-017-0424-2 ID - Chalmers2017 ER - TY - JOUR AU - Szklarczyk, D. AU - Morris, J. H. AU - Cook, H. PY - 2017 DA - 2017// TI - The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible JO - Nucleic Acids Res VL - 45 UR - https://doi.org/10.1093/nar/gkw937 DO - 10.1093/nar/gkw937 ID - Szklarczyk2017 ER - TY - JOUR AU - Shannon, P. AU - Markiel, A. AU - Ozier, O. PY - 2003 DA - 2003// TI - Cytoscape: a software environment for integrated models of biomolecular interaction networks JO - Genome Res VL - 13 UR - https://doi.org/10.1101/gr.1239303 DO - 10.1101/gr.1239303 ID - Shannon2003 ER - TY - JOUR AU - Liu, Z. AU - Meng, J. AU - Li, X. PY - 2018 DA - 2018// TI - Identification of Hub genes and key pathways associated with two subtypes of diffuse large B-cell lymphoma based on gene expression profiling via integrated bioinformatics JO - Biomed Res Int VL - 2018 ID - Liu2018 ER - TY - JOUR AU - Newman, A. M. AU - Liu, C. L. AU - Green, M. R. PY - 2015 DA - 2015// TI - Robust enumeration of cell subsets from tissue expression profiles JO - Nat Methods VL - 12 UR - https://doi.org/10.1038/nmeth.3337 DO - 10.1038/nmeth.3337 ID - Newman2015 ER - TY - JOUR AU - Kandoth, C. AU - McLellan, M. D. AU - Vandin, F. PY - 2013 DA - 2013// TI - Mutational landscape and significance across 12 major cancer types JO - Nature VL - 502 UR - https://doi.org/10.1038/nature12634 DO - 10.1038/nature12634 ID - Kandoth2013 ER - TY - JOUR AU - Petitjean, A. AU - Achatz, M. I. AU - Borresen-Dale, A. L. AU - Hainaut, P. AU - Olivier, M. PY - 2007 DA - 2007// TI - TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes JO - Oncogene VL - 26 UR - https://doi.org/10.1038/sj.onc.1210302 DO - 10.1038/sj.onc.1210302 ID - Petitjean2007 ER - TY - JOUR AU - Barbieri, C. E. AU - Baca, S. C. AU - Lawrence, M. S. PY - 2012 DA - 2012// TI - Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer JO - Nat Genet VL - 44 UR - https://doi.org/10.1038/ng.2279 DO - 10.1038/ng.2279 ID - Barbieri2012 ER - TY - JOUR AU - Geng, C. AU - He, B. AU - Xu, L. PY - 2013 DA - 2013// TI - Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover JO - Proc Natl Acad Sci USA VL - 110 UR - https://doi.org/10.1073/pnas.1304502110 DO - 10.1073/pnas.1304502110 ID - Geng2013 ER - TY - JOUR AU - Boysen, G. AU - Barbieri, C. E. AU - Prandi, D. PY - 2015 DA - 2015// TI - SPOP mutation leads to genomic instability in prostate cancer JO - Elife VL - 4 UR - https://doi.org/10.7554/eLife.09207 DO - 10.7554/eLife.09207 ID - Boysen2015 ER - TY - JOUR AU - Gao, N. AU - Zhang, J. AU - Rao, M. A. PY - 2003 DA - 2003// TI - The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes JO - Mol Endocrinol VL - 17 UR - https://doi.org/10.1210/me.2003-0020 DO - 10.1210/me.2003-0020 ID - Gao2003 ER - TY - JOUR AU - Alvarez-Cubero, M. J. AU - Martinez-Gonzalez, L. J. AU - Robles-Fernandez, I. PY - 2017 DA - 2017// TI - Somatic mutations in prostate cancer: closer to personalized medicine JO - Mol Diagn Ther VL - 21 UR - https://doi.org/10.1007/s40291-016-0248-6 DO - 10.1007/s40291-016-0248-6 ID - Alvarez-Cubero2017 ER - TY - JOUR AU - Fan, C. AU - Quan, R. AU - Feng, X. PY - 2006 DA - 2006// TI - ATM activation is accompanied with earlier stages of prostate tumorigenesis JO - Biochim Biophys Acta VL - 1763 UR - https://doi.org/10.1016/j.bbamcr.2006.08.026 DO - 10.1016/j.bbamcr.2006.08.026 ID - Fan2006 ER - TY - JOUR AU - Zhang, C. AU - Li, Z. AU - Qi, F. AU - Hu, X. AU - Luo, J. PY - 2019 DA - 2019// TI - Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma JO - Ann Transl Med VL - 7 UR - https://doi.org/10.21037/atm.2019.10.84 DO - 10.21037/atm.2019.10.84 ID - Zhang2019 ER - TY - JOUR AU - Zhang, C. AU - Shen, L. AU - Qi, F. AU - Wang, J. AU - Luo, J. PY - 2020 DA - 2020// TI - Multi-omics analysis of tumor mutation burden combined with immune infiltrates in bladder urothelial carcinoma JO - J Cell Physiol VL - 235 UR - https://doi.org/10.1002/jcp.29279 DO - 10.1002/jcp.29279 ID - Zhang2020 ER - TY - JOUR AU - Chabanon, R. M. AU - Pedrero, M. AU - Lefebvre, C. AU - Marabelle, A. AU - Soria, J. C. AU - Postel-Vinay, S. PY - 2016 DA - 2016// TI - Mutational landscape and sensitivity to immune checkpoint blockers JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0903 DO - 10.1158/1078-0432.CCR-16-0903 ID - Chabanon2016 ER - TY - JOUR AU - Velasco, M. A. AU - Uemura, H. PY - 2018 DA - 2018// TI - Prostate cancer immunotherapy: where are we and where are we going? JO - Curr Opin Urol VL - 28 UR - https://doi.org/10.1097/MOU.0000000000000462 DO - 10.1097/MOU.0000000000000462 ID - Velasco2018 ER - TY - JOUR AU - Ahmad, N. PY - 2004 DA - 2004// TI - Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer JO - FASEB J VL - 18 UR - https://doi.org/10.1096/fj.03-0848hyp DO - 10.1096/fj.03-0848hyp ID - Ahmad2004 ER - TY - JOUR AU - Zhang, Z. AU - Hou, X. AU - Shao, C. PY - 2014 DA - 2014// TI - Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-14-1916 DO - 10.1158/0008-5472.CAN-14-1916 ID - Zhang2014 ER - TY - JOUR AU - Li, J. AU - Wang, R. AU - Kong, Y. PY - 2017 DA - 2017// TI - Targeting Plk1 to enhance efficacy of olaparib in castration-resistant prostate cancer JO - Mol Cancer Ther VL - 16 UR - https://doi.org/10.1158/1535-7163.MCT-16-0361 DO - 10.1158/1535-7163.MCT-16-0361 ID - Li2017 ER - TY - JOUR AU - Subudhi, S. K. AU - Vence, L. AU - Zhao, H. PY - 2020 DA - 2020// TI - Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer JO - Sci Transl Med VL - 12 UR - https://doi.org/10.1126/scitranslmed.aaz3577 DO - 10.1126/scitranslmed.aaz3577 ID - Subudhi2020 ER -